Fundraising

Cairn Therapeutics is raising a Series A round to support our First in Human Phase I trial, which is scheduled to begin in Q1’25. We have completed all necessary preclinical studies and are finalizing our Drug Product, set for completion by Q4’24. With our IND submission planned for the end of 2024, your investment will be pivotal in advancing our groundbreaking cancer therapies.